Literature DB >> 26387398

Factors Affecting Successfulness of Vaginal Pessary Use for the Treatment of Pelvic Organ Prolapse.

Orawan Lekskulchai, Preecha Wanichsetakul.   

Abstract

BACKGROUND: Pelvic organ prolapse can cause adverse events affecting the lives of the women. Vaginal pessary is a conservative treatment, which is not expensive and safe. For the patient with medical condition, vaginal pessary would be the first choice of treatment.
OBJECTIVE: To study the factors those affect the success of the vaginal pessary use for treatment ofpelvic organ prolapse. MATERIAL AND
METHOD: Historical data ofpatients who visited urogynecology clinic, Thammasat University hospital from January 2009 through December 2013, were collected. The SPSS program was used for statistical analysis with p-value < 0.05.
RESULTS: Of 252 women with pelvic organ prolapse, median age was 67 years (range 29-92 years). Most patients, 78.2%, had severe POP (stage 3-4). 194 women were treated with vaginal pessary. 83.5% of these patients could use continuously more than 3 months. The open ring was the most common using pessary. 48.1% of the patients who could use pessary continuously can self-remove and insert the device. Anterior vaginal wall and the vaginal length were significantly higher with the successful users. The most common complication was the presence of abnormal vaginal discharge, and more common in the patient with donut pessary.
CONCLUSION: The open ring is the device that can be used easily and has fewer complications,followed by ring with support. Short vaginal length is afactor that cannot use the pessary. It seems that relaxed anterior wall and longer vaginal length might help hold the pessary in the vagina.

Entities:  

Mesh:

Year:  2015        PMID: 26387398

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  1 in total

1.  Ring and Gellhorn pessaries used in patients with pelvic organ prolapse: a retrospective study of 8 years.

Authors:  Junfang Yang; Jinsong Han; Fuli Zhu; Yu Wang
Journal:  Arch Gynecol Obstet       Date:  2018-07-05       Impact factor: 2.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.